SHIVOM

SHIVOM

WHAT IS SHIVOM

THE SHIVOM ECOSYSTEM

Shivom is creating a genomics ecosystem on the blockchain. We will offer an open marketplace for healthcare providers to add their apps and services, alongside genomic data analytics and personalized medicine.

Transform genomic data into useable information Break down data silos Help accelerate clinical trials Facilitate drug research and development Sponsor sequencing projects to get access to relevant data

OUR VISION

Accelerate the age of genomics

Every one of the 7.6 billion people on earth has a unique code held within their genes that unlocks the secrets to appearance, ancestry, intellectual capabilities, health, and fitness. But, this code’s ability to reveal predisposition to disease has been overlooked.

Improve global health

Now is the time for concerted, community-wide development for the “genomical” challenges of the coming decade. Currently, a few key players hold the monopoly on genomic data and make huge profits from selling it to 3rd parties, usually without sharing the earnings with the data donor.

Jumpstart genome-based precision medicine

We are changing the dynamics of the global healthcare market. We are utilizing the most advanced technologies including blockchain, cloud computing, genome sequencing, artificial intelligence, and big data analytics to bring medical genomics into a new era.

Ensure the next level of data privacy

We are at the forefront of data security. We use state-of-the-art cryptography to add additional security levels to our platform that go well beyond blockchain technology for decentralization, protecting each user’s data from cybercriminals.

Rating

We assign the Shivom project a "Stable" rating.

The idea of the Shivom project is to introduce blockchain technology into one of the most promising sectors in the public health market — genomics and precision medicine. Each Shivom platform user will have not only reliable access to scientific knowledge, but can also manage their genome data for their own benefit. Realizing this idea, they argue, is necessary for the health of each individual and of the population of the planet as a whole.

Despite the interesting idea, the platform is currently in development and the alpha version is yet to be released.

Most of the risks are associated with a high likelihood of excess tokens appearing in the market in the medium and long term. When checking OMX tokens and their parameters using Etherscan.io, projects with the same token name, OMX, were found.

In addition to all the risks detailed in the appropriate chapter of this review, it is not clear why the project has so little publicly-available information. We were unable to get a look at the marketing strategy or the business plan. A large number of details directly affecting the success of the ICO, the attractiveness of the token and the development of the project, were not disclosed by the project team for analysis.

The voluminous, challenging-to-read white paper is introductory in nature; it offers specialized terminology and information about the genomics market, but does not contain basic details necessary for an investor to make a decision about participation in the token sale.

The project is "raw" and needs further quality work. We recommend that the developers provide all details and nuances of the token sale, the project’s development, financial planning, the platform’s expansion, etc. for public access and start interacting with their potential audience.

Team and Stakeholders

The Shivom team consists of 6 founders and 11 team members.

Axel Schumacher. Co-Founder and CEO.

Since 2017 he has been a faculty member of the Blockchain Research Institute in Toronto, working on healthcare in blockchain. Between 2014–2016 he worked as global marketing manager and precision medicine expert for Genedata, where he created a new platform for the top 25 pharmaceutical companies. Previously he worked as a manager of the Blood Donor Biobank, at that time the largest biobank in the world, where he successfully helped to create a new product, PlasmaRef Panels, for the diagnostics and pharmaceutical industry. He was a co-founder and manager of the BioKEP company, and group leader for Alzheimer Epigenetics and manager of the genomics facility of the Klinikum Rechts der Isar, Germany’s top ranked clinic, and built several laboratories in Germany and Canada. Axel worked as project manager for the Centre for Addiction and Mental Health (CAMH) and is the inventor of epigenetic microarray technology.


He graduated from the University of Cologne majoring in Epigenetics and Medical genetics.

Axel is the author of over 30 highly cited publications; he holds 8 certificates and 3 patents.

Gourish Singla. Co-founder and COO.

Gourish has worked as COO for Shivom for more than a year. Previously he worked as a director for Kusum Chemicals for over 6 years. Kusum Chemicals is the largest importer and distributor of PVC chemicals in North India.

SALLY EAVES. Co-founder and CMO.

Sally is an official member of the Forbes Technology Council. Currently she is a senior advisor on strategy to Nuggets, a platform for e-commerce. Since 2016 she has been CEO and director of the Sally Eaves Consultancy. Concurrently Sally is also CTO of Mind Fit, CIO of Intrapreneur International Ltd. and director of global education at the British Young Asian Entrepreneurs Association.

PER LIND. Co-founder and CSO.

Per is a co-founder of the IOTA foundation. He is a partner of ASEAN and APAC, assisting such companies as HYPR Biometric Security, Apptivo, Opinator, Secunia, Falcon.io and iMotions. Per has been vice-president of business development for more than 11 years at MyCosmic, a company that provides international roaming for smartphones. For more than 19 years he has been director of Farmor Cloud Factory Co. Ltd., a consulting company for the sales and marketing of hardware and software.

Akash Gaurav. Co-founder and CTO.

Akash is the founder of the Auxledger Foundation, Blockchain Lab, India. CEO at Auxesis Group, an innovative company with advanced expertise in fintech and blockchain technology. Auxesis has been consistently ranked in the top 100 blockchain companies in the world. He works as a blockchain network advisor to Cashaa. Mr. Gaurav has participated in 10 projects such as MEMS Department Drupal Website, Restructured & Revamped, Eureka!, Asia’s largest b-model competition, and founded and developed FCOF, E-Cell IITB, etc.

Titles and awards: Institute Technical Special Mention, Merit Scholarship, Merit Award & Scholarship.

Kumar Gaurav. Co-Founder and Chief Technology Advisor.

Kumar is the founder of Cashaa, a banking platform that enables making deals with millions of people. He is currently the chairman of the Auxesis Group. He is also an advisor to Satoshi Studios. Previously he was co-founder of the DarWinsurance insurance platform and the BTC2BID Bitcoin exchange platform.
Certificates

Microsoft certified .NET Professional (MCP)

Sun Certified JAVA Programmer (SCJP 6)

The team is the strongest aspect of this project. We highlight the co-founder, Axel Schumacher, who is a notable professional in the field of precision medicine, particularly genetics. Equally important is the experience of the other co-founders responsible for technical issues, marketing, and strategic development of the ecosystem. Other team members with relevant expertise are also responsible for these areas.

The co-founders and various members of the team are advisors to and founders of other projects and currently occupy different positions at other companies, which is of course proof of their experience and professionalism, but the question is whether they would be able to pay due attention to the Shivom project while combining work in several positions and responsibilities for other companies

GENOMICS FOR EVERYONE

Accurate, comprehensive interpretation of your genome will only be possible when the biomedical community has analyzed enough genome sequences representing the full range of natural human variation. However, today, many ethnic and geographical populations are still underrepresented in public databases.

OUR TEAM

DR. AXEL SCHUMACHER

CO-FOUNDER & CEO

HENRY INES

CHIEF INNOVATION OFFICER

DR. RASHAD IBRAHIM

HEAD OF MIDDLE EAST

AJIT SINGH KULAR

HEAD OF DIGITAL MARKETING

TING PENG

PUBLIC RELATIONS MANAGER

GOURISH SINGLA

CO-FOUNDER & COO

AKASH GAURAV

CO-FOUNDER & CTO

AGAM KANSAL

VP MARKETING

STEPHANE LAURENT

HEAD OF CHINESE SUBCONTINENT

KAYLEEN SCHREIBER

DESIGN LEAD

SALLY EAVES

CO-FOUNDER & CMO

DR. NATALIE PANKOVA

CHIEF SCIENTIFIC OFFICER

CHARLES LESLIE

INVESTMENT LEAD

AZAM SHAGHAGHI

HEAD OF PUBLIC RELATIONS

PIERRE MAAREK

INVESTMENT LEAD

SHIVOM INNOVATION COUNCIL

TAAVI RÕIVAS

DAVID ORBAN

DR. IRSHAAD EBRAHIM

DR. JAY SANDERS

GEOFF HANCOCK

DR. KAMALA K MADDALI

ANTANAS GUOGA

DR. WILLIAM YASNOFF

OUR ADVISORS

DAVID DRAKE

IAN SCARFFE
Ian Scarffe is a serial entrepreneur, investor and consultant with business experience from around the world.As a leading entrepreneur, Ian is on a personal mission to develop a culture of entrepreneurship, helping startups achieve their full potential as well as helping to expand existing companies. Ian has founded ‘Binkplus’, a startup incubator in Europe.

ELIE GALAM
A mathematician and alternative investments expert, Elie founded Panorama Partners in 2011, a New York-based hedge fund that uses algorithms to find arbitrage opportunities in financial derivatives. Prior to Panorama, he was a Portfolio Manager for Two Sigma investments, a 40 bn dollar quantitative hedge fund. Elie received a Master's in Applied Mathematics from Harvard University and a Master's in Engineering from Ecole Centrale Paris.

for more information:

https://shivom.io/

author:

BTT username: rivaldo2020

BTT profile link: https://bitcointalk.org/index.php?action=profile;u=2051385